The popularity of Ozempic, Wegovy, and other glucon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in recent years ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Ozempic and other GLP-1 agonist medications have risen in popularity over the last few years due to their touted blood sugar management and weight-loss effects. However, some supp ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...